BIOLOG-ID
4.1.2021 14:00:18 CET | Business Wire | Press release
The members of the Supervisory Board of Biolog-id elected Jean-Luc Bélingard as Chairman of the Supervisory Board of the company. He succeeds to its founder, Jean-Claude Mongrenier, who will assume the vice-presidency. This appointment comes into effect on January 1st , 2021.
Biolog-id has developed unique expertise in connected healthcare solutions and offers a breakthrough innovation that makes the life cycle of sensitive therapeutic products (red blood cell concentrates, platelets, plasma, chemotherapy preparations) more reliable, and secures their administration to patients.
Jean-Luc Bélingard is a seasoned industry leader with an international career in the pharmaceutical, life sciences and diagnostics sector. He comes with 40 years of experience with some of the largest pharmaceutical companies, notably at Roche where he was a member of the Group Executive Committee (Basel, Switzerland). Since 2011, he has served as CEO and then Chairman of bioMérieux before taking on, in 2018, the Vice-Presidency of Institut Mérieux.
"It is an honor and a responsibility for me to join and support Biolog-id in a new stage of its development. Biolog-id is a company with a promising future. It patented a connected solution, Medical Device certified, which offers great added value in terms of public healthcare, with significant economic and social impacts. It makes it possible to strengthen the safety of medical procedures, improve the working conditions of healthcare professionals, reduce operational costs and prevent the loss of sensitive health products. This set of added values is a guarantee of quality and safety for patients and healthcare establishments. By accepting this mandate as Chairman of the Supervisory Board, I hope, along with the management team and employees, to contribute to the success of this innovative company”, declares Jean-Luc Bélingard.
"As the founder of the company, I am happy to hand over my functions to Jean-Luc Bélingard, with whom I share the same vision of the company, based on humanist values. Biolog-id will benefit from its extensive experience in the pharmaceutical industry and its governance skills. In particular, he will be responsible for leading the introduction of Biolog-id on the Nasdaq, its listing being planned as of 2022 ", announces Jean-Claude Mongrenier.
"The appointment of Jean-Luc Bélingard as Chairman of the Supervisory Board will allow Biolog-id to benefit from a high-level leadership executive with an indisputable influence. This is an important appointment for the international development of the company and for its upcoming IPO. I am convinced that he will be able to capitalize on this flagship of the FrenchTech 120 to make it go through new major stages, "confirms Jacques Simonnet, founder of the Xerys Group which has already funded Biolog-id up to about fifty million euros and is preparing a capital increase of more than 20 million euros.
About Biolog-id
Biolog-id has designed an intelligent and patented solution for the management and traceability of sensitive healthcare products (red blood cell concentrates, plasma, platelets, chemotherapy preparations), in order to optimize their supply chain from donor to patient. Present in North America, Europe, the Middle East, India and the Asia-Pacific region, Biolog-id has about a hundred employees around the world. The Biolog-connect® solution is protected by more than 100 international patents. Biolog-id is the property of its founder and the Xerys Funds.
Web site: www.biolog-id.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005413/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ki Reply and Data Reply Lay the Strategic Foundation for AI Innovation at Siemens Healthineers with “Cerebra”9.3.2026 10:53:00 CET | Press release
Ki Reply and Data Reply, the Reply Group companies specialised respectively in AI-powered software development and data-driven solutions, have partnered with the “CRM Excellence” department of medical technology company Siemens Healthineers to develop “Cerebra“, an advanced AI platform designed to deliver rapid, relevant insights across marketing and sales. The concept proved so successful that “Cerebra” was evolved into an Agent Factory, which now standardises, simplifies, and accelerates the deployment of AI agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309083025/en/ To support labour-intensive manual research in marketing, and sales, Siemens Healthineers now leverages “Cerebra“, an AI-powered knowledge platform that uses specialised AI agents to consolidate internal and external data. In the fast-moving and highly regulated medical technology market, the ability to analyse information accurately and quickly is
AMINA Becomes First Regulated Bank on 21X, Europe’s First Fully Regulated DLT Trading and Settlement Venue9.3.2026 08:30:00 CET | Press release
Along with Tokeny, the combined tokenisation suite creates a complete tokenisation infrastructure, from regulated custody to onchain trading and settlement AMINA Bank AG (“AMINA”), a Swiss Financial Market Supervisory Authority (FINMA)-regulated crypto bank with global reach, today announces it has become a listing sponsor on 21X, the first fully regulated distributed ledger technology trading and settlement system (DLT TSS) in the European Union. AMINA is the first regulated bank to join the 21X ecosystem as a listing sponsor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309758719/en/ AMINA, 21X and Tokeny partner for end-to-end solution Combined with AMINA’s existing collaboration with Tokeny for onchain asset issuance, the partnership creates a complete tokenisation infrastructure that addresses a major constraint of institutional adoption: the absence of an end-to-end pathway connecting regulated traditional asset c
GigaDevice Strengthens Global Presence at Embedded World 2026, Showcasing System-Level Innovations for Humanoid Robotics, Industry, and Edge AI9.3.2026 08:00:00 CET | Press release
Wide range of demonstrations on display at Hall 5, 5-129 throughout the March 10-12 show GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced its participation at Embedded World 2026 (Hall 5, Booth 5-129), with the strong presence at the show demonstrating the company’s commitment to the global market and the strategic emphasis that it has placed on the EMEA region, reinforcing its ambition to empower customers with advanced embedded solutions. “Embedded World is a cornerstone of our global engagement strategy,” said Dr. Reiner Jumpertz, GigaDevice VP and General Manager in the EMEA region. “This year, we are not only showcasing our technical excellence but also highlighting our evolution into a system-level enabler, a trusted partner that supports customers in building smarter, more connected applications.” “By combining our high-performance GD32 MCUs, industry-proven Flash memory, and a
Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin9.3.2026 07:00:00 CET | Press release
Cetaphil’s new AM/PM Serums are powered by unique Gallic-AOX Power™ Technology, a patent-pending antioxidant complex clinically designed to sync to your skin’s circadian rhythm and support skin resilience Delivers advanced antioxidant protection by day1 and accelerated repair by night, with visible results in as little as 7 days2 In global testing, Gallic Acid demonstrated 2x greater antioxidant efficacy than Vitamin C3 Co-developed with dermatologists and rigorously tested for sensitive skin to deliver high performance without compromising tolerance Galderma (SIX: GALD) today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antioxidant Serums, a breakthrough daily system clinically designed to defend skin by day and support accelerated repair by night for sensitive, stressed skin. While antioxidant serums are a cornerstone of modern skincare, the category has largely been developed without sensitive sk
Report: GCs Say They Are Bullish on Europe9.3.2026 07:00:00 CET | Press release
ADVANT research underscores opportunity amid political and economic headwinds, but challenges remain Business confidence around prospects for investment and growth in Europe is riding high despite recent economic and geopolitical challenges, according to new research among GCs across Europe and the U.S. For its report released today – Europe’s Opportunity Outlook – European law firm association ADVANT surveyed or interviewed more than 800 GCs in France, Germany, Italy and the United States, and found thatfour out of five (82%) GCs said their company views continental Europe as attractive for corporate investment and commercial growth. Meanwhile, two-thirds (66%) report their organization has made Europe more of a priority in light of recent geopolitical and regulatory risks. Looking further ahead, a significant majority (83%) believe their organization is likely or very likely to expand or invest further within existing European markets in the next three to five years. A similar propor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom